Item 9 Labs Corp (INLB)
0.00
USD |
OTCM |
Jun 17, 16:00
Item 9 Labs SG&A Expense (Quarterly): 3.354M for June 30, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
June 30, 2023 | 3.354M |
March 31, 2023 | 3.746M |
December 31, 2022 | 3.333M |
September 30, 2022 | 7.472M |
June 30, 2022 | 3.884M |
March 31, 2022 | 4.226M |
December 31, 2021 | 3.248M |
September 30, 2021 | 7.136M |
June 30, 2021 | 2.298M |
March 31, 2021 | 2.017M |
December 31, 2020 | 1.440M |
September 30, 2020 | 2.703M |
June 30, 2020 | 0.9191M |
March 31, 2020 | 1.022M |
December 31, 2019 | 1.211M |
September 30, 2019 | 1.900M |
June 30, 2019 | 1.226M |
March 31, 2019 | 1.076M |
December 31, 2018 | 0.7489M |
September 30, 2018 | 0.2512M |
June 30, 2018 | 0.2258M |
March 31, 2018 | 0.0189M |
December 31, 2017 | 0.0421M |
September 30, 2017 | 0.0553M |
June 30, 2017 | 0.0352M |
Date | Value |
---|---|
March 31, 2017 | 0.0399M |
December 31, 2016 | 0.0306M |
September 30, 2016 | 0.1846M |
June 30, 2016 | 0.1696M |
March 31, 2016 | 0.2172M |
December 31, 2015 | 0.2002M |
September 30, 2015 | 0.2455M |
June 30, 2015 | 0.2377M |
March 31, 2015 | 0.3559M |
December 31, 2014 | 0.2724M |
September 30, 2014 | 0.2873M |
June 30, 2014 | 0.2899M |
March 31, 2014 | 0.3102M |
December 31, 2013 | 0.2815M |
September 30, 2013 | 0.2837M |
June 30, 2013 | 0.5815M |
March 31, 2013 | 0.4024M |
December 31, 2012 | 0.3252M |
June 30, 2012 | 0.4295M |
March 31, 2012 | 2.221M |
December 31, 2011 | 0.0103M |
September 30, 2011 | 0.0131M |
June 30, 2011 | 0.3824M |
March 31, 2011 | 0.1845M |
December 31, 2010 | 0.0076M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.9191M
Minimum
Jun 2020
7.472M
Maximum
Sep 2022
3.008M
Average
2.703M
Median
Sep 2020
SG&A Expense (Quarterly) Benchmarks
NovaBay Pharmaceuticals Inc | 3.346M |
Palatin Technologies Inc | 2.033M |
iBio Inc | 2.722M |
Theriva Biologics Inc | 1.933M |
Oragenics Inc | 1.797M |